Drug
Paritaprevir clinical trials
Also written ABT-450.
- studies test it
- 41
- open now
- 0
- in phase 3
- 20
- first study started
- 2009
How studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
41 studies that test it; most in 2015 (14)
| Year | Studies |
|---|---|
| 2009 | 3 |
| 2010 | 3 |
| 2011 | 2 |
| 2012 | 4 |
| 2013 | 6 |
| 2014 | 5 |
| 2015 | 14 |
| 2016 | 3 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 13
- Phase 3
- 20
- Phase 4
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 34 · Other 7
AbbVie (22) · AbbVie (prior sponsor, Abbott) (9) · Abbott (3) · Nova Scotia Health Authority (1) · Kirby Institute (1) · Humanity and Health Research Centre (1) · Assiut University (1) · American Research Corporation (1)
Often tested with
Tested in the same studies.
Ritonavir (40) · Ombitasvir (33) · Dasabuvir (28) · Ribavirin (26) · Sofosbuvir (3) · Ombitasvir/Paritaprevir/Ritonavir (3) · ABT-072 (2) · Glecaprevir and pibrentasvir (1)
Studies
Open first, then newest update. How each study uses paritaprevir is read from its arms, and is right about nine times in ten.
Testing it · 41
- Understanding HCV Reinfection Rates in an Incarcerated Population After Cure With Interferon Free HCV TreatmentActive, not recruitingPhase 4Nova Scotia Health AuthorityNCT02460133Written as Paritaprevir
- A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) InfectionCompletedPhase 3AbbVieNCT02219490Written as ABT-450/r/ABT-267
- Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/PCompletedPhase 3Kirby InstituteNCT02634008Written as Paritaprevir/ritonavir/ombitasvir
- A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) InfectionCompletedPhase 3AbbVieNCT02167945Written as ABT-450/r/ABT-267
- Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral TherapyTerminatedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT02194998Written as Paritaprevir/ritonavir/ombitasvir (PTV/r/OBT)
- DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO)CompletedPhase 2/3Humanity and Health Research CentreNCT02555943Written as Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir
- A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced AdultsCompletedPhase 3AbbVie (prior sponsor, Abbott)NCT01715415Written as ABT-450/r/ABT-267, ABT-333
- Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT- 267 (ABT-450/r/ABT-267) in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus (HCV) InfectionCompletedPhase 3AbbVieNCT02023112Written as ABT-450/r/ABT-267
- A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated CirrhosisCompletedPhase 3AbbVie (prior sponsor, Abbott)NCT01704755Written as ABT-450/r/ABT-267, ABT-333
- A Study to Evaluate Chronic Hepatitis C InfectionCompletedPhase 3AbbVie (prior sponsor, Abbott)NCT01716585Written as ABT-450/r/ABT-267, ABT-333
- Ombitasvir/ Paritaprevir / Ritonavir Plus Ribavirin in Management HCV and End-stage Kidney DiseaseCompletedPhase 4Assiut UniversityNCT03499639Written as Ombitasvir / Paritaprevir / Ritonavir /Ribavirin Oral Tablet
- Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Subjects With Genotype 1a Chronic Hepatitis C Virus InfectionCompletedPhase 3AbbVieNCT02609659Written as ombitasvir/paritaprevir/ritonavir and dasabuvir
- A Study to Investigate HCV Response Rates in Real World Patients: HEARTLAND StudyCompletedPhase 4American Research CorporationNCT03710252Written as paritaprevir/ritonavir/ombitasvir + dasabuvir +/- ribavirin
- ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-Administered With Ribavirin (RBV) in Treatment Naïve and Treatment Experienced Asian Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Compensated CirrhosisCompletedPhase 3AbbVieNCT02517528Written as ABT-450/r/ABT-267
- Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) in Japanese Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) InfectionCompletedPhase 3AbbVieNCT02023099Written as ABT-450/r/ABT-267
- A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment BeforeCompletedPhase 3AbbVieNCT01854697Written as ABT-450/r/ABT-267, ABT-333
- A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) for Treatment of Chronic Hepatitis C Infection in Treatment-experienced AdultsCompletedPhase 3AbbVieNCT01854528Written as ABT-450/r/ABT-267, ABT-333
- A Study to Evaluate ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Japanese Adults With Chronic Hepatitis C Virus InfectionCompletedPhase 2AbbVie (prior sponsor, Abbott)NCT01672983Written as ABT-450/ritonavir, ABT-267
- An Open-label, Single Arm, Phase 2 Study to Evaluate ABT-450/r/ABT-267 and ABT-333 With Ribavirin (RBV) in Adults With Genotype 1 HCV Infection Taking Methadone or BuprenorphineCompletedPhase 2AbbVieNCT01911845Written as ABT-450/r/ABT-267
- A Study to Evaluate the Safety and Antiviral Effect of ABT-450/Ritonavir and ABT-530 Coadministered With and Without Ribavirin in Adults With Genotype 3 Hepatitis C (HCV) InfectionCompletedPhase 2AbbVieNCT02068222Written as ABT-450/ritonavir (r)
See all 41 studies that test paritaprevir →
Given in every arm · 8 — paritaprevir is usual care beside what is tested
- A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric SubjectsCompletedPhase 2/3AbbVieNCT02486406Written as Paritaprevir mini tablet
- A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b InfectionCompletedPhase 3AbbVie (prior sponsor, Abbott)NCT01767116Written as ABT-450/r/ABT-267, ABT-333
- A Study to Evaluate the Safety and Effect of the Experimental Drugs ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Subjects With Chronic Hepatitis CCompletedPhase 3AbbVie (prior sponsor, Abbott)NCT01674725Written as ABT-450/r/ABT-267, ABT-333
- A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV)CompletedPhase 2AbbVieNCT01995071Written as ABT-450/r/ABT-267, ABT-333
- A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 CoinfectionCompletedPhase 2/3AbbVieNCT01939197Written as ABT-450/r/ABT-267
- A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a InfectionCompletedPhase 3AbbVieNCT01833533Written as ABT-450/r/ABT-267, ABT-333
- Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected SubjectsCompletedPhase 2AbbVie (prior sponsor, Abbott)NCT01563536Written as ABT-450
- ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected PatientsCompletedPhase 2AbbVie (prior sponsor, Abbott)NCT01464827Written as ABT-450
Codes
What other systems call paritaprevir · ClinicalTrials.gg INT006403
- MeSH (NLM) C585405paritaprevirOne source NLM
- UNII (FDA) OU2YM37K86PARITAPREVIRConfirmed FDA, NLM
- RxNorm 1597373One source FDA
- NCI Thesaurus C123879ParitaprevirOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C585405 | paritaprevir | One source NLM |
| UNII (FDA) | OU2YM37K86 | PARITAPREVIR | Confirmed FDA, NLM |
| RxNorm | 1597373 | — | One source FDA |
| NCI Thesaurus | C123879 | Paritaprevir | One source FDA |
Also registered as paritaprevir dihydrate (UNII HRQ5901O78 · RxNorm 1600436).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.